Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
June 03, 2019 01:15 ET
|
Novartis Pharma AG
Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer...
Xolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
June 03, 2019 01:00 ET
|
Novartis Pharma AG
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate...
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
June 01, 2019 07:30 ET
|
Novartis Pharma AG
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973)[1] After a median of 42 months follow-up, the survival rate was 70.2% for...
Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
May 30, 2019 01:15 ET
|
Novartis Pharma AG
Low dose QMF149 (indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to...
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
May 24, 2019 16:12 ET
|
Novartis Pharma AG
Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulvestrant alone...
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
May 24, 2019 12:42 ET
|
Novartis Pharma AG
One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA Annualized cost of Zolgensma is USD...
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
May 24, 2019 12:30 ET
|
Novartis Pharma AG
SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age...
Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event
May 23, 2019 01:15 ET
|
Novartis Pharma AG
Driving growth through cutting edge pipeline with 15 in-market blockbusters and more than 25 potential blockbusters in development, including 10+ planned launches by 2021 Strong progress on...
Novartis verkauft ihren Teil des Klybeckareals an die Schweizer Firma Central Real Estate Basel AG
May 22, 2019 08:00 ET
|
Novartis Pharma AG
Novartis hat heute bekanntgegeben, dass sie ihre Arealteile und Gebäude im Werk Klybeck an die Firma Central Real Estate Basel AG verkauft hat. Die Central Real Estate Basel AG gehört zu einer...
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
May 22, 2019 01:15 ET
|
Novartis Pharma AG
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting...